Loading

Engineered treatment
to reduce atherosclerosis

Trialed and tested

Reduction in cholesterol and other lipids
Plaque reduction within 4 weeks

CAVADEX® reduces atherosclerosis

CAVADEX® captures cholesterol and transports the cholesterol out of the body in the urine.

What is CAVADEX®

In 2016, German scientists discovered that a compound “Cyclodextrin” reduced arterial plaque in mice. Cholrem Pty Ltd researched cyclodextrins and engineered a specific cyclodextrin with enhanced cholesterol transport capabilities. This new cyclodextrin "CAVADEX®" is a ring-shaped structure made from starch. CAVADEX® is only several atoms wide and has a cavity in the middle. The outside of the ring is attracted to water and the inside cavity is attracted to oils and lipids (like cholesterol).

When CAVADEX® circulates around the vascular system, cholesterol is sucked into the cavity and the cholesterol binds with the CAVADEX® and is transported out of the body via the urine.

CAVADEX reverses Heart Disease

CAVADEX® reduces lipid levels and arterial plaque within 4 weeks.

CAVADEX


The only cyclodextrin proven safe in the treatment of atherosclerosis

Science Articles

Nature

Cyclodextrin reprogrammed the cells in plaques, leading to increased transport of the dissolved cholesterol away from the plaques...

Science Daily

Cyclodextrin dissolves cholesterol crystals and reduces atherosclerotic plaques...

Huffington Post

can actually solubilize cholesterol and dissolve the plaques...

Science Daily

Soaked up cholesterol and removed it...

Norwegian University of Science and Technology

have the potential in lowering deaths caused by atherosclerosis...


CAVADEX® removes plaque and cholesterol

plaque reduced in just 4 weeks

A recent study by the University Hospital in Bonn, Germany discovered that cyclodextrin melts away cholesterol crystals (the main cause of arterial plaque that clogs arteries) and reduced existing plaque within just 4 weeks. The cyclodextrin bound to and dissolved the cholesterol crystals from the plaque of mice, leading to transport of the dissolved cholesterol away from the plaques. The same effects were seen in human plaque samples treated with cyclodextrin.

Article : Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

Improve Liver function

Another study by the University of Texas Southwestern Medical Center, Dallas, Texas, shows the treatment of Npc1-deficient mice slows cholesterol sequestration in major organs and improves liver function. This study shows that cyclodextrin is effective in mobilizing entrapped cholesterol in late stage NPC disease leading to improved liver function.

Article : Systemic administration of 2-hydroxypropyl-B-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.




Cyclodextrin has shown to extend lifespan by almost 10% in mice

Mice treated with CAVADEX® showed higher neurological scores than compared with the mice given saline only..

Mice on CAVADEX® lived 10% longer.

CAVADEX® cleares the vascular system and can extend lifespan.

In 2014 at the University of Texas Southwest Medical Center, a study was conducted on the effects of Cyclodextrin administered to mice. They studied the lifespan of mice treated systemically with either saline or Cyclodextrin at weekly intervals starting at 49 days of age until death. In each case, half of the males and females were given Cyclodextrin and the remaining mice received only saline.

During the study, the mice were graded on their neurological function. There were no gender related differences in the neurological scores. This score, which broadly measures neurological function, declines as the animal’s condition deteriorates.
It is clear that Cyclodextrin treated mice showed higher neurological scores than compared with the mice given saline only.

All the mice given saline only had died by 98 days whereas the majority of those receiving Cyclodextrin died in the week following. This shows an almost 10% improvement in lifespan.

The human trial of CAVADEX conducted by Cholrem has consistantly shown the scientific evidence proving the benefits of Cyclodextrin on mice also has simular benefits on humans. It would be fair to assume that based on the science, humans treated with CAVADEX would also experience a simular benefit of lifespan extention as the mice.